January 22, 2013

Harnessing the Power of HDAC Inhibitors in Ovarian Cancer

Apicidin is a fungal metabolite with antiparasitic activity, and this histone deacetylase (HDAC) inhibitor has shown antiproliferative activity against various cancer cell lines. Korean researchers focused on the molecular mechanisms of apicidin in human ovarian cancer SKOV-3 cells and found that the agent has the potential to hinder cancer cell migration and invasion. They describe the mechanism of action by which apicidin reduced HDAC4 in this particular cancer. 

RESULT: Histone deacetylase inhibitor, apicidin, inhibits human ovarian cancer cell migration via class II histone deacetylase 4 silencing
Cancer Letters (PubMed) | Dec 28, 2012 (Free abstract. Full text $31.50)

Platinum-based chemo leads to modest survival benefits in metastatic ovarian cancer so pairing it with other agents may offer a therapeutic boost. To that end, investigators in New York successfully married the experimental HDAC inhibitor panobinostat with doxorubicin and carboplatin. They explain why this triplet of agents proved to be “synergistic” in ovarian cancer cell lines, including SKOV-3. 

RESULT: The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines
Investigational New Drugs (PubMed) | Dec 02, 2011 (Free abstract. Full text $39.50)

==================================

for further reading, go to the source or write us!